Analyzing Solta Medical (SLTM) & Agilent Technologies (A)
Solta Medical (NASDAQ: SLTM) and Agilent Technologies (NYSE:A) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, earnings, risk and dividends.
This is a breakdown of recent ratings and recommmendations for Solta Medical and Agilent Technologies, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Agilent Technologies pays an annual dividend of $0.60 per share and has a dividend yield of 0.9%. Solta Medical does not pay a dividend. Agilent Technologies pays out 101.7% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Agilent Technologies has raised its dividend for 2 consecutive years.
Earnings and Valuation
This table compares Solta Medical and Agilent Technologies’ revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Agilent Technologies||$4.47 billion||4.87||$684.00 million||$0.59||114.42|
Agilent Technologies has higher revenue and earnings than Solta Medical. Solta Medical is trading at a lower price-to-earnings ratio than Agilent Technologies, indicating that it is currently the more affordable of the two stocks.
This table compares Solta Medical and Agilent Technologies’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Agilent Technologies beats Solta Medical on 8 of the 9 factors compared between the two stocks.
About Solta Medical
Solta Medical, Inc. designs, develops, manufactures and markets professional and consumer energy-based medical device systems for aesthetic applications. The Company’s systems are cleared by the United States Food and Drug Administration (FDA) for dermatological procedures performed in the physician led, professional assist, and personal care markets. The Company’s portfolio of products includes six brands that are primarily designed for aesthetic applications: The Fraxel re:pair system provides ablative laser skin resurfacing while the non-ablative Fraxel platform and Clear + Brilliant systems provide treatment for skin rejuvenation. The Thermage system provides non-invasive skin tightening and the Liposonix system provides non-invasive body contouring. Isolaz and CLARO provide options to resolve acne. In January 2014, Valeant Pharmaceuticals International Inc ‘s wholly-owned subsidiary Valeant Pharmaceuticals International acquired Solta Medical Inc.
About Agilent Technologies
Agilent Technologies, Inc. provides application focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. The Company serves the life sciences, diagnostics and applied chemical markets. It has three business segments: life sciences and applied markets business, diagnostics and genomics business, and Agilent CrossLab business. Its life sciences and applied markets business segment offers instruments and software that enable customers to identify, quantify and analyze the physical and biological properties of substances and products, as well as enable customers in the clinical and life sciences research areas to interrogate samples at the molecular level. Its diagnostics and genomics business segment includes the reagent partnership, pathology, companion diagnostics, genomics and the nucleic acid solutions businesses. Its Agilent CrossLab business segment spans the entire lab with its consumables and services portfolio.
Receive News & Ratings for Solta Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Solta Medical and related companies with MarketBeat.com's FREE daily email newsletter.